Navigation Links
Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
Date:10/30/2009

ROCKVILLE, Md., Oct 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 third quarter financial results in a press release to be issued after 8:00 am local time on Friday, November 6, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. local time on Friday, November 6, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 814-8448 (International: 1 (703) 639-1367.

A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning November 6, 2009 at 1:00 pm through November 8, 2009 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter pass code 1394584.

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 12th annual Inventors Recognition Reception at Purdue Research Park of West ... member in recognition of outstanding contributions to, and success with, commercializing discoveries from ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile market ... prices have dropped dramatically. The quarterly average price of ... to $276 in Q4 2016.  There are now 120 ... of $116, up from just 28 a year ago ... According to Maxine Most , Acuity Market Intelligence ...
(Date:1/18/2017)... 2017  In vitro diagnostic (IVD) companies were very ... (M&A), and Kalorama Information expects that trend to continue ... shifting. Generally, uncertainty in reimbursement and healthcare reform in ... changed the acquisitions landscape. Instead of looking to buy ... partners outside of their home country and also to ...
Breaking Biology News(10 mins):